Citadel Advisors
IPSC icon

Citadel Advisors’s Century Therapeutics IPSC Stock Holding History

Citadel Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$310K Buy
+126,470
New +$289K ﹤0.01% 11044
2026
Q1 		– Sell
-319,457
Closed -$672K – 13586
2025
Q4 		$318K Sell
319,457
-41,368
-11% -$25.2K ﹤0.01% 10007
2025
Q3 		$180K Buy
360,825
+174,291
+93% +$94K ﹤0.01% 11373
2025
Q2 		$104K Buy
186,534
+177,425
+1,948% +$95.2K ﹤0.01% 11311
2025
Q1 		$4.34K Sell
9,109
-511,119
-98% -$384K ﹤0.01% 13900
2024
Q4 		$525K Buy
520,228
+501,742
+2,714% +$683K ﹤0.01% 8443
2024
Q3 		$31.6K Sell
18,486
-26,674
-59% -$52.3K ﹤0.01% 12383
2024
Q2 		$115K Sell
45,160
-9,132
-17% -$28.9K ﹤0.01% 10715
2024
Q1 		$227K Sell
54,292
-45,627
-46% -$193K ﹤0.01% 10067
2023
Q4 		$332K Buy
99,919
+41,328
+71% +$75.3K ﹤0.01% 8967
2023
Q3 		$117K Buy
58,591
+34,146
+140% +$90.8K ﹤0.01% 10696
2023
Q2 		$77.2K Sell
24,445
-27,755
-53% -$89.5K ﹤0.01% 11284
2023
Q1 		$181K Sell
52,200
-78,958
-60% -$347K ﹤0.01% 10345
2022
Q4 		$673K Buy
+131,158
New +$1.24M ﹤0.01% 7632
2022
Q3 		– Sell
-59,966
Closed -$632K – 13092
2022
Q2 		$504K Buy
59,966
+27,508
+85% +$270K ﹤0.01% 8632
2022
Q1 		$409K Buy
+32,458
New +$430K ﹤0.01% 9852
2021
Q4 		– Sell
-24,044
Closed -$605K – 14270
2021
Q3 		$605K Buy
+24,044
New +$651K ﹤0.01% 9403

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Citadel Advisors's IPSC Position: Q2 2026 in Review

Citadel Advisors opened a new position in Century Therapeutics (IPSC) in Q2 2026: 126,470 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #11044 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IPSC as recently as Q4 2025.

Citadel Advisors first reported a position in IPSC in Q3 2021 and has held it in 17 quarters since. The position peaked at $673K in Q4 2022. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Citadel Advisors held 126,470 shares of Century Therapeutics worth $310K as of Q2 2026.
  • Century Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Century Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11044 holding.
  • Citadel Advisors first reported a position in Century Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • Citadel Advisors's Century Therapeutics position peaked at $673K in Q4 2022.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.